Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 21

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 21
---

or divestiture, if any, may be limited, although the terms of a divesture may include future royalties, earn-outs or similar terms, any
of which could fail to be earned or received. Any restructuring, divestiture or closing may fail to realize the anticipated 15% reduction
in operating costs in fiscal year 2025 compared to fiscal year 2024 that the Company announced on December 17, 2024.

<div align='center'>8</div>

Stockholders may suffer substantial dilution if certain provisions in the May 2024 Series Warrants are utilized.

On May 29, 2024, we closed on such date
the May 2024 Offering, which included the May 2024 Series A Warrants and May 2024 Series B Warrants, pursuant
to the May 2024 Placement Agency Agreement.

If the May 2024 Series B Warrants
are exercised by way of an alternative cashless exercise, such exercising holder will receive three times the number of shares of Common
Stock they would receive in a cash exercise for each May 2024 Series B Warrant they exercise, without any cash payment to us.
In addition, the May 2024 Series A Warrants and May 2024 Series B Warrants each include a provision that resets their
exercise price in the event of a reverse split of our Common Stock, to a price equal to the lesser of (i) the then exercise price
and (ii) lowest volume weighted average price (VWAP) during the period commencing five trading days immediately preceding and the
five trading days commencing on the date we effect a reverse stock split in the future with a proportionate adjustment to the number
of shares underlying the applicable warrant,

In addition, and subject to certain exemptions,
the May 2024 Series A Warrants provide for an adjustment to the exercise price and number of shares underlying the May 2024 Series A
Warrants if we sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter into an agreement to sell, or grant
any right to reprice (excluding Exempt Issuances, as defined in the May 2024 Placement Agency Agreement), or otherwise dispose of
or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any shares of Common Stock, at an effective
price per share less than the exercise price of the May 2024 Series A Warrants then in